Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AF74 | ISIN: US44842L1035 | Ticker-Symbol: H7T1
Siehe auch HUTCHMED CHINA LIMITED
Tradegate
01.11.24
14:35 Uhr
17,300 Euro
+0,100
+0,58 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
HUTCHMED CHINA LIMITED ADR Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
16,80017,70011:17
17,10017,30001.11.

Aktuelle News zur HUTCHMED CHINA LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHutchmed China receives first milestone payment for Takeda drug sales4
DoHutchmed to receive $20m Fruzaqla milestone payment 2
DoHUTCHMED (China) Limited: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda61HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces that it will receive a US$20 million...
► Artikel lesen
DoHUTCHMED (00013): TOTAL VOTING RIGHTS1
DoHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED TO RECEIVE FIRST COMMERCIAL MILESTONE PAYMENT FOLLOWING OVER US$200 MILLION IN FRUZAQLA (FRUQUINTINIB) ...3
DoHutchmed China Ltd - First Commercial Milestone Payment-
DoHutchmed China Ltd - Total Voting Rights-
21.10.HUTCHMED (00013): VESTING OF AWARDS UNDER THE LONG TERM INCENTIVE PLAN-
21.10.Hutchmed China Ltd - Vesting of awards under the LTIP-
16.10.Hutchmed reports positive results from AstraZeneca lung cancer collaboration4
16.10.HUTCHMED Ltd - 6-K, Report of foreign issuer1
16.10.Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate-
16.10.HUTCHMED (China) Limited: HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase ...59- New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer - - MET is a common biomarker in this setting for patients who develop...
► Artikel lesen
16.10.HUTCHMED (00013): HUTCHMED ANNOUNCES THAT TAGRISSO PLUS ORPATHYS DEMONSTRATED HIGH, CLINICALLY MEANINGFUL RESPONSE RATE IN LUNG CANCER PATIENTS WITH HIGH ...2
11.10.HUTCHMED (NASDAQ:HCM) Stock Price Down 2.3% - Should You Sell?1
10.10.AIM WINNERS & LOSERS: Windward rises; Hutchmed recovers1
24.09.Hutchmed partner Takeda gets Japanese approval for Fruzaqla4
24.09.HUTCHMED Ltd - 6-K, Report of foreign issuer2
24.09.HUTCHMED (China) Limited: HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda3
24.09.HUTCHMED (00013): HUTCHMED ANNOUNCES JAPAN APPROVAL FOR FRUZAQLA (FRUQUINTINIB) RECEIVED BY TAKEDA2
Seite:  Weiter >>
142 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1